A Pap smear does not actually test for HPV. It looks for abnormal cell changes on the cervix that HPV might eventually cause, and its sensitivity for catching those changes is moderate at best. In large studies, a single Pap smear detects only about 61% of high-grade precancerous lesions, meaning it misses roughly 4 in 10 cases. A dedicated HPV test, which identifies the virus’s genetic material directly, is significantly more sensitive. Understanding what each test does, and where the Pap smear falls short, helps you make sense of your screening results.
What a Pap Smear Actually Detects
A Pap smear collects cells from the surface of your cervix so a lab technician can examine them under a microscope. The technician is looking for cells that appear abnormal in shape, size, or organization. These changes can be early signs that HPV has started damaging cervical tissue, potentially on a path toward precancer or cancer. But the test is purely visual. It cannot tell you whether HPV is present in your body, only whether your cells have started to look different.
An HPV test works completely differently. Because the virus can’t be grown in standard lab cultures, the test searches for HPV’s DNA or RNA directly in a sample of cervical cells. This means it can identify an active infection before any visible cell changes have occurred, sometimes years before a Pap smear would flag anything.
Sensitivity: How Much a Pap Smear Catches
The sensitivity of a test refers to how well it identifies people who truly have a problem. For a Pap smear, the numbers are lower than many people expect. A large study published in JAMA found that thin-layer Pap smears detected high-grade precancerous lesions (CIN 3 or higher) with a sensitivity of about 61% in women under 30. In women 30 and older, sensitivity dropped to roughly 46% for the same lesions, and to just 36% for slightly less advanced precancers.
Across broader clinical settings, the picture is similar. Pooled data on liquid-based cytology show a sensitivity of about 76% for detecting moderate-to-severe precancers, but the range in individual studies stretches from as low as 52% to as high as 94%. That wide range reflects real-world variability: how the sample was collected, how well preserved the cells were, and how experienced the person reading the slide was all affect accuracy.
The practical takeaway is that a single normal Pap result doesn’t guarantee nothing is wrong. False negative rates for precancerous lesions can range from about 6% to 48% depending on the clinical context. This is precisely why guidelines recommend repeating the test on a regular schedule rather than relying on a single result.
Where Pap Smears Struggle Most
Pap smears are weakest at detecting a specific type of cervical abnormality: glandular lesions, which can develop into adenocarcinoma. These abnormal glandular cells often resemble normal cells under the microscope. In a study of 49 patients with cervical adenocarcinoma, the sensitivity of a single Pap smear was between 45% and 76%. Half of the reviewed slides that were initially called negative actually contained cancer cells, but the abnormal cells had been mistaken for normal-looking endocervical or lower-segment endometrial cells. In 16 of those 18 missed slides, the abnormal cells were abundant. The problem wasn’t that there were too few cells to find. It was that they didn’t look obviously abnormal.
This is a meaningful blind spot because adenocarcinoma has been making up a growing share of cervical cancers in recent decades, even as squamous cell cancers have declined thanks to screening.
How HPV Testing Compares
HPV testing consistently outperforms the Pap smear for sensitivity. While specificity is similar for both tests (about 97% for Pap smears versus 94% for HPV testing, meaning both are good at correctly identifying healthy women), HPV testing catches more true positives. The slight trade-off is that HPV testing flags some infections that would clear on their own, which can lead to extra follow-up visits.
When both tests are performed together, a strategy called co-testing, sensitivity climbs to as high as 99%. That near-perfect detection rate comes at the cost of slightly lower specificity (92% to 95%), meaning a few more women will get flagged for follow-up who turn out to be fine. But for catching precancers, co-testing is the most thorough option available.
What Happens With an Unclear Pap Result
Not every Pap result comes back clearly normal or clearly abnormal. A common middle-ground result is “atypical squamous cells of undetermined significance,” often abbreviated ASC-US. This means the cells look slightly off but not definitively precancerous. When this happens, labs typically perform a reflex HPV test on the same sample to determine whether a high-risk HPV strain is present. If it is, you’ll likely be referred for a closer examination called a colposcopy. If the HPV test is negative, the abnormal-looking cells are much less likely to be meaningful, and you’ll usually just return for follow-up screening on a normal schedule.
A less common result, ASC-H, means atypical cells that can’t rule out a higher-grade lesion. Current guidelines generally recommend colposcopy for this result, though there is growing support for using HPV testing in these cases as well to reduce unnecessary biopsies.
Current Screening Recommendations
The U.S. Preventive Services Task Force recommends cervical cancer screening for women aged 21 to 65. For women 21 to 29, the recommendation is a Pap smear every three years. Women 30 to 65 have three options: a Pap smear alone every three years, a high-risk HPV test alone every five years, or co-testing (Pap plus HPV) every five years.
The longer interval for HPV-based screening reflects the test’s higher sensitivity. Because it catches more problems, you can safely go longer between screens. No screening is recommended before age 21, regardless of sexual activity, because cervical cancer is extremely rare in younger women and HPV infections at that age almost always resolve on their own.
Why Regular Screening Still Works
Despite the Pap smear’s limitations in any single round of testing, repeated screening over time is remarkably effective. A population-based study found that screening within a three-year window reduced the odds of advanced cervical cancer by 83% compared to women who hadn’t been screened in five years. Women who attended screening consistently, with at least two screens spaced at least 10 months apart and no gap longer than 30 months, saw a 90% reduction in advanced cervical cancer.
The reason is straightforward: cervical cancer develops slowly. Most HPV infections take 10 to 20 years to progress from initial infection to cancer. A Pap smear that misses a precancerous change this year has a good chance of catching it at the next screening, while it’s still treatable. The test doesn’t need to be perfect in a single round. It needs to be repeated, and it needs to be repeated on schedule. More frequent screening than every three years did not provide additional benefit in reducing advanced cancers, so the three-year interval strikes the right balance between catching problems and avoiding unnecessary procedures.